IMMUNE-RELATED
ADVERSE EVENTS
irAEs are the defining safety consideration in immunotherapy. They're manageable when identified early — and dangerous when missed. Patients who navigate them best are those who knew what to expect before treatment started.
What This Means for Patients
An irAE is when the immune system — activated by immunotherapy to attack cancer — also attacks healthy tissue. The checkpoint inhibitors that remove the off-switches tumors exploit don't selectively remove them only near the tumor. They affect the whole immune system. Severity depends on the specific drug, whether combination therapy is used, and individual immune physiology. The same drug can produce colitis in one patient and pneumonitis in another.
The irAE Grading System
All irAEs are classified Grade 1–4. The grade — not just the organ affected — determines management.
- 1
Grade 1 — Mild
Mild symptoms. Managed with monitoring and supportive care. Treatment typically continues without interruption.
- 2
Grade 2 — Moderate
Moderate symptoms requiring minor intervention. Steroid therapy may begin. Some irAEs at this grade prompt a treatment hold pending resolution.
- 3
Grade 3 — Severe
Severe symptoms requiring significant medical intervention. Treatment is usually held. High-dose oral or IV steroids initiated. Specialist consultation often required.
- 4
Grade 4 — Life-Threatening
Immediate hospitalization and intervention required. Treatment typically discontinued permanently. IV methylprednisolone plus specialist management.
irAEs Requiring the Highest Urgency
Most irAEs are organ-specific and manageable. These five presentations have the narrowest window between onset and serious harm.
Pneumonitis
New or worsening respiratory symptoms — cough, dyspnea — during or after checkpoint inhibitor therapy. Difficult to distinguish from infection or disease progression without imaging. Prompt CT chest is the first step.
Colitis
Severe diarrhea, blood in stool, abdominal cramping. Grade 3–4 colitis may require IV steroids and hospitalization. Steroid-refractory cases require infliximab.
Myocarditis
Rare but potentially fatal. New chest pain, palpitations, or dyspnea during immunotherapy warrants urgent ECG and troponin. Threshold for cardiac evaluation should be low — early diagnosis is critical.
Hypophysitis and Adrenal Crisis
Severe headache, profound fatigue, low blood pressure, hyponatremia. Pituitary or adrenal involvement can present with nonspecific symptoms that are easy to miss. Adrenal crisis is life-threatening without immediate steroid replacement.
Neurological irAEs
Encephalitis, meningitis, peripheral neuropathy, Guillain-Barré-like syndrome. Uncommon but serious. Any new neurological symptoms during immunotherapy warrant prompt MRI and CSF evaluation.
Key Numbers
- 50–60%Grade 3–4 irAEs: Dual CheckpointApproximate rate of serious immune-related adverse events with nivolumab plus ipilimumab combination — significantly higher than monotherapy.
- 15–20%Grade 3–4 irAEs: PD-1 MonotherapySerious irAE rate for PD-1 inhibitor monotherapy — lower than combination therapy, but still requires active monitoring.
- Weeks–MonthsPotential Onset WindowirAEs can appear at any point during treatment and up to months after the last dose. Monitoring extends beyond the active treatment period.
Who This Is Relevant For
All patients on checkpoint inhibitor therapy. The specific risk profile — which irAEs are most likely, at what rate — differs between agents and regimens. Understanding the irAE profile of your specific regimen, not just immunotherapy in general, is part of informed treatment consent.
Benefits and Limitations
Manageable With Early Recognition
- Steroids work for most irAEsCorticosteroids are effective across the majority of immune-mediated inflammation presentations.
- Structured monitoring catches early signalsRoutine bloods, imaging, and clinical reviews are built into immunotherapy programs specifically to detect irAEs before escalation.
Requires Active Vigilance
- Onset timing is unpredictableSevere irAEs can occur in patients who previously tolerated the drug well — and after stopping treatment.
- Endocrine irAEs may be permanentThyroid and adrenal function changes may require lifelong management regardless of treatment status.
Frequently Asked Questions
irAE Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Understand the irAE Profile of Your Specific Immunotherapy Regimen?
Each regimen has a distinct irAE profile — knowing which organs are most at risk and what symptoms to watch for before starting treatment is part of informed care. Upload your treatment plan and our team will review what monitoring applies to your specific situation.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.